KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Non-Current Debt (2019 - 2025)

Historic Non-Current Debt for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $8.6 billion.

  • Royalty Pharma's Non-Current Debt rose 2957.9% to $8.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 billion, marking a year-over-year increase of 2957.9%. This contributed to the annual value of $6.6 billion for FY2024, which is 781.33% up from last year.
  • Per Royalty Pharma's latest filing, its Non-Current Debt stood at $8.6 billion for Q3 2025, which was up 2957.9% from $7.0 billion recorded in Q2 2025.
  • Royalty Pharma's Non-Current Debt's 5-year high stood at $8.6 billion during Q3 2025, with a 5-year trough of $5.8 billion in Q1 2021.
  • Moreover, its 5-year median value for Non-Current Debt was $6.6 billion (2024), whereas its average is $6.6 billion.
  • As far as peak fluctuations go, Royalty Pharma's Non-Current Debt plummeted by 1377.85% in 2023, and later soared by 2957.9% in 2025.
  • Over the past 5 years, Royalty Pharma's Non-Current Debt (Quarter) stood at $7.1 billion in 2021, then fell by 13.77% to $6.1 billion in 2022, then grew by 0.27% to $6.1 billion in 2023, then rose by 7.81% to $6.6 billion in 2024, then rose by 29.5% to $8.6 billion in 2025.
  • Its Non-Current Debt stands at $8.6 billion for Q3 2025, versus $7.0 billion for Q2 2025 and $6.6 billion for Q1 2025.